AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca has launched a real-world study titled ‘Early Treatment of Heart Failure: a Non-interventional Study Program of Patients With Heart Failure and Initiated on Dapagliflozin (EVOLUTION-HF DEallEF)’ to explore the use of dapagliflozin in heart failure patients in Germany. This study aims to gather observational data on treatment patterns, symptoms, and healthcare utilization, given the significant global burden of heart failure.
The study focuses on dapagliflozin, a drug approved by the European Commission for heart failure treatment, regardless of ejection fraction or diabetes status. It is intended to improve the quality of life and reduce morbidity and mortality in heart failure patients.
Designed as an observational cohort study, it will prospectively follow patients with different ejection fractions (HFpEF, HFmrEF, HFrEF) who are treated with dapagliflozin according to local standards.
The study began on April 25, 2024, with a primary completion date yet to be announced. The last update was submitted on July 8, 2025, indicating ongoing recruitment and data collection.
This study could influence AstraZeneca’s stock performance positively by reinforcing dapagliflozin’s market position in heart failure treatment. Investors may view this as a strategic move to solidify AstraZeneca’s competitive edge in the cardiovascular market.
The study is ongoing, with further details available on the ClinicalTrials portal.